Safe and effective poxvirus vectors--NYVAC and ALVAC.
This paper describes the development and in vitro/in vivo characterization of two highly attenuated recombinant poxvirus vectors. The vectors, NYVAC and ALVAC, exhibit a restricted host range and a greatly enhanced degree of attenuation following inoculation into a range of animal species by a variety of routes. The safety profile of these vectors, together with their demonstrated ability to induce both humoral and cell-mediated immune responses to extrinsic antigens, makes them ideal candidates for use as vaccines in both human and veterinary disease situations.
Virogenetics Corporation, Rensselaer Technology Park, Troy, NY.
E
E
Paoletti
J
J
Tartaglia
J
J
Taylor
D000818:Animals; D000831:Animals, Newborn; D018150:Avipoxvirus / Q000235:genetics* / Q000276:immunology; D002171:Canaries; D003673:Defective Viruses / Q000235:genetics* / Q000276:immunology; D005822:Genetic Vectors; D016679:Genome, Viral; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009928:Organ Specificity; D012449:Safety; D013045:Species Specificity; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014616:Vaccinia virus / Q000235:genetics* / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology
C078788:ALVAC vaccine; C078787:NYVAC vaccine; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D014765:Viral Vaccines